With six marketed drugs, ADCs are presently recognized as a potent class of targeted anticancer therapies, with the potential to be used to treat a variety of other disease indications. The success of such products can be attributed to their ability to effectively identify and eliminate disease associated cells / pathogens, with substantially lower risk of treatment related side effects.
Key Inclusions
An insightful competitiveness analysis of biological targets, featuring a [A] three-dimensional bubble representation that highlights the targets that are being evaluated for ADC development, taking into consideration the number of lead molecules based on a particular target, phase of development of candidate therapies, number of clinical trials and number of target disease indications, and [B] a five-dimensional spider-web analysis, highlighting the most popular biological targets based on a number of relevant parameters, including affiliated publications, grants received to support research on a particular target, number of industry players involved in drug development efforts based on a singular target and geographical distribution of associated clinical trials.
To order this 600+ page report, which features 190+ figures and 280+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/antibody-drug-conjugates-market-5th-edition-2019-2030/270.html
The USD 15 billion (by 2030) financial opportunity within this market has been analyzed across the following segments:
The Antibody Drug Conjugates Market (5th Edition), 2019-2030.” report features the following companies, which we identified to be key players in this domain:
Table of Contents
1. Preface
2. Executive Summary
3. Introduction
5. Company and Drug Profiles
6. Key Therapeutic Areas
7. Key Opinion Leaders
8. Target Competitiveness Analysis
9. Partnerships and Collaborations
10. Funding and Investment Analysis
11. Patent Analysis
12. Academic Grants
13. Key Commercialization Strategies
14. Promotional Analysis
15. Combination Therapies
16. Novel Conjugation Technology Platforms
17. Assessment of Non-Clinical Data, First in Human Dosing
18. Cost Price Analysis
19. Case Study: Contract Manufacturing of ADC
20. Case Study: Companion Diagnostics for ADC Therapeutic
21. Market Forecast and Opportunity Analysis
22. Swot Analysis
23. Conclusion
24. Executive Insights
25. Appendix 1: Tabulated Data
To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/antibody-drug-conjugates-market-5th-edition-2019-2030/270.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
- The whole point of certification is that it independently and impartially verifies that you are complying to a standard. Irrespective of regardless
- Marketing automation is one of the great processes that help businesses not only to automate their repetitive marketing tasks.
- Instructing K-12 wont be an easy endeavor, and it really is been manufactured additional challenging and a lot more long lasting
- 100% real and updated exam questions with answers for all famous certifications. Pass in first attempt .Error Free Products with 24/7 Customer Support.Special discount offer for all customer